Topiramate is under clinical development by PrevEp and currently in Phase I for Status Epilepticus. According to GlobalData, Phase I drugs for Status Epilepticus have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Topiramate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Topiramate overview

Topiramate (PrevEp-004) is under development for the treatment of drug resistant status epilepticus and neonatal seizures. The drug candidate acts by targeting AMPA receptor, sodium channels, GABA (A) receptor, carbonic anhydrase 2 and carbonic anhydrase 4. It is administered by intravenous route.

PrevEp overview

PrevEp biotech company focused in the epilepsy research and development of new therapies for epilepsy prevention. PrevEp is headquartered in Bethesda, Maryland, the US.

For a complete picture of Topiramate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.